Twist Bioscience Corporation (NASDAQ:TWST) Receives Average Rating of “Moderate Buy” from Analysts

Twist Bioscience Corporation (NASDAQ:TWST) has earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $46.50.

A number of brokerages recently commented on TWST. Evercore raised their target price on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. Robert W. Baird set a $50.00 price target on shares of Twist Bioscience in a research note on Tuesday, February 3rd. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Guggenheim raised their price objective on shares of Twist Bioscience from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a report on Friday, March 27th.

Insider Buying and Selling

In other news, insider Dennis Cho sold 5,000 shares of the stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $49.93, for a total value of $249,650.00. Following the sale, the insider directly owned 138,581 shares in the company, valued at approximately $6,919,349.33. This trade represents a 3.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Adam Laponis sold 7,000 shares of Twist Bioscience stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $50.00, for a total value of $350,000.00. Following the completion of the transaction, the chief financial officer owned 130,031 shares of the company’s stock, valued at approximately $6,501,550. This trade represents a 5.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 48,190 shares of company stock worth $2,234,695 over the last three months. 3.08% of the stock is owned by insiders.

Institutional Investors Weigh In On Twist Bioscience

A number of hedge funds have recently bought and sold shares of the stock. Quarry LP acquired a new position in shares of Twist Bioscience during the third quarter worth about $28,000. Smartleaf Asset Management LLC raised its holdings in Twist Bioscience by 70.6% in the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after acquiring an additional 442 shares in the last quarter. Strategic Advocates LLC lifted its stake in Twist Bioscience by 562.7% in the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after acquiring an additional 906 shares during the last quarter. SBI Securities Co. Ltd. lifted its stake in Twist Bioscience by 68.9% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after acquiring an additional 571 shares during the last quarter. Finally, National Bank of Canada FI acquired a new position in Twist Bioscience during the 3rd quarter worth approximately $46,000.

Twist Bioscience Stock Up 1.4%

Twist Bioscience stock opened at $50.21 on Friday. The company has a market capitalization of $3.08 billion, a PE ratio of -39.23 and a beta of 2.20. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78. Twist Bioscience has a fifty-two week low of $23.30 and a fifty-two week high of $57.88. The firm has a 50 day moving average price of $46.84 and a 200 day moving average price of $37.12.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The firm had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. The business’s revenue for the quarter was up 16.9% compared to the same quarter last year. Research analysts expect that Twist Bioscience will post -2.12 earnings per share for the current year.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.